Life Scientist > Health & Medical

Pathologists back down from GTG attack

11 July, 2003 by Melissa Trudinger

The Royal College of Pathologists of Australasia (RCPA) and associated genetics organisations, including the Human Genetics Society of Australia, have retracted and clarified recent statements made in a letter to state and Federal government officials, which suggested that Melbourne biotech company Genetic Technologies would seek to enforce the breast cancer gene patents licensed to it by Myriad Genetics.


Benefits outweigh gene therapy risks

09 July, 2003 by Melissa Trudinger

The risks of developing cancer as a side-effect of gene therapy were outweighed by the potential benefit to the patients, one of the scientists involved in gene therapy clinical trials said yesterday at the XIX International Congress of Genetics.


Panbio scores FDA approval, world first

09 July, 2003 by Jeremy Torr

Bribane diagnostic biotech Panbio has become the first company ever to rate US FDA approval for a West Nile virus (WNV) immunoassay diagnostic kit.


BioFirst lures researchers

09 July, 2003 by Jeremy Torr

NSW’s BioFirst awards have attracted two top overseas researchers to the state, in the first of this year’s appointments for overseas experts.


Mouse model could ID mental illness gene

09 July, 2003 by Melissa Trudinger

A schizophrenic mouse model has led the way to identification of a gene potentially predisposing humans to the devastating human mental illness.


Huntington's test tale proves our unpredictability

08 July, 2003 by Graeme O'Neill

Within a year of the identification in 1993 of the huntingtin gene, which in mutant form causes the fatal brain disorder Huntington's disease, geneticists devised a test to detect the mutation, and offered it to families with a history of the disease.


Granny off the hook in menopause mystery

07 July, 2003 by Graeme O'Neill

Geneticists appear to have failed in their latest attempt to indict human grandmothers in the court of life for indirectly visiting menopause upon their daughters.


Garvan reaps surprise windfall

20 June, 2003 by Jeremy Torr

The Garvan Institute celebrated 40 years of sharp end research into cancer and associated diseases last week -- and in the process gained over $1million in research funds.


Norwood Abbey planning clinical trial

19 June, 2003 by Melissa Trudinger

Norwood Abbey is in the midst of planning an international clinical trial examining the use of its Gonadotropin Releasing Hormone (GnRH) analogue drugs to revive the immune system in patients with HIV/AIDS.


Aust HIV vaccine trial now recruiting subjects

06 June, 2003 by Jeremy Torr

The first HIV vaccine developed in Australia is expected to go to clinical trials within months, with results expected in mid 2004.


Woolcock, Hunter join forces in sleep research network

04 June, 2003 by Susan Williamson

The Woolcock Institute of Medical Research in Sydney and the Hunter Medical Research Institute (HMRI) in Newcastle have joined forces to form what they claim is the largest respiratory and sleep research network in the southern hemisphere.


Tailoring chemotherapy to specific cancer cells

03 June, 2003 by Susan Williamson

As part of the Australian Society for Medical Research's (ASMR) Medical Research Week, the Amgen Medical Researcher Award was presented today to Dr Ricky Johnstone from Melbourne's Peter MacCallum Cancer Centre.


GTG cleans slate, opens door to new business deals

29 May, 2003 by Melissa Trudinger

Melbourne company Genetic Technologies (GTG) has introduced a twist in its licensing strategy by offering companies the chance to be forgiven for past transgressions of GTG's non-coding DNA patents.


EvoGenix swaps dreams for reality with Start grant

29 May, 2003 by Jeremy Torr

EvoGenix has won $900,000 from the latest round of federal government R&D Start grant awards, adding a major boost to its R&D program over the next two years.


Cytopia claims success in early-stage anti-cancer drug trial

28 May, 2003 by Melissa Trudinger

Melbourne drug discovery company Cytopia has claimed its lead anti-cancer compounds were active in vitro against a common form of childhood cancer.


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd